Maintenance immunosuppression is a key part of preventing acute and chronic rejection and should be individualized and offer different mechanisms and less side effects. Strategies should be devised to increase long-term compliance. Acute rejections should be treated aggressively to decrease risk of chronic rejection. Novel biomarkers should be utilized in a judicious manner. Emerging therapies offer promise but need more studies.